7V7 Stock Overview
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Acticor Biotech SAS Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.40 |
52 Week High | €5.72 |
52 Week Low | €2.62 |
Beta | -0.029 |
1 Month Change | -3.68% |
3 Month Change | n/a |
1 Year Change | -38.85% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -49.10% |
Recent News & Updates
Recent updates
Shareholder Returns
7V7 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | -3.2% | 2.0% |
1Y | -38.8% | -25.4% | 5.9% |
Return vs Industry: 7V7 underperformed the German Biotechs industry which returned -25.4% over the past year.
Return vs Market: 7V7 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
7V7 volatility | |
---|---|
7V7 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7V7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7V7's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2013 | 29 | Gilles Avenard | www.acticor-biotech.com |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It’s product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19).
Acticor Biotech SAS Fundamentals Summary
7V7 fundamental statistics | |
---|---|
Market cap | €10.53m |
Earnings (TTM) | -€18.65m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs 7V7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
7V7 income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €0 |
Gross Profit | €0 |
Other Expenses | €18.65m |
Earnings | -€18.65m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.42 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 2,160.1% |
How did 7V7 perform over the long term?
See historical performance and comparison